Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).
about
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic reviewUpdate on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents.Preclinical Activity of Simvastatin Induces Cell Cycle Arrest in G1 via Blockade of Cyclin D-Cdk4 Expression in Non-Small Cell Lung Cancer (NSCLC)
P2860
Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Economic evaluation of bevaciz ...... mall cell lung cancer (NSCLC).
@ast
Economic evaluation of bevaciz ...... mall cell lung cancer (NSCLC).
@en
type
label
Economic evaluation of bevaciz ...... mall cell lung cancer (NSCLC).
@ast
Economic evaluation of bevaciz ...... mall cell lung cancer (NSCLC).
@en
prefLabel
Economic evaluation of bevaciz ...... mall cell lung cancer (NSCLC).
@ast
Economic evaluation of bevaciz ...... mall cell lung cancer (NSCLC).
@en
P2860
P356
P1476
Economic evaluation of bevaciz ...... mall cell lung cancer (NSCLC).
@en
P2093
Chun-Ru Chien
Ya-Chen Tina Shih
P2860
P304
P356
10.2147/CEOR.S27770
P407
P577
2012-07-25T00:00:00Z